光子计数CT对左心室肥厚表型患者的组织表征研究
研究连续纳入182例左心室肥厚患者(肥厚型心肌病72例、转甲状腺素蛋白心肌淀粉样变47例、继发性左心室肥厚63例),行光子计数CT包括晚期碘强化和细胞外容积评估,其中83例(46%)在±12个月内行心脏磁共振。光子计数CT可区分不同病因的组织模式,与心脏磁共振在形态功能指标、细胞外容积和晚期碘强化与晚期钆强化的一致性上高度相关。作者认为光子计数CT可提供与心脏磁共振相当的评估,支持在心脏磁共振禁忌、不可行或无法诊断时使用。
要点
- 光子计数CT可区分转甲状腺素蛋白心肌淀粉样变、肥厚型心肌病和继发性左心室肥厚的组织模式。
- 光子计数CT与心脏磁共振在左心室质量指数、射血分数和细胞外容积上高度相关。
- 晚期碘强化与晚期钆强化逐节段一致率达99%至100%,检测晚期钆强化的AUC为0.994。
核心结论
- 光子计数CT提供与心脏磁共振相当的室腔几何、功能和心肌纤维化/细胞外容积评估,同时可完成冠状动脉造影,支持在心脏磁共振禁忌、不可行或无法诊断时使用。
研究设计与样本
- 连续纳入182例左心室肥厚患者(肥厚型心肌病72例、转甲状腺素蛋白心肌淀粉样变47例、继发性左心室肥厚63例),行光子计数CT包括晚期碘强化和光子计数CT衍生的细胞外容积;其中83例(46%)在±12个月内行心脏磁共振(中位间隔-12天),评估形态功能指标、细胞外容积和晚期碘强化与晚期钆强化的一致性。
关键影像表现/征象
- 转甲状腺素蛋白心肌淀粉样变表现为最高的左心室质量指数(中位数104 g/m2)、最大的晚期碘强化范围(中位数17/17节段)和最高的细胞外容积(中位数47%)。
- 肥厚型心肌病表现为斑片状纤维化(中位数4个强化节段),细胞外容积居中(31%)。
- 继发性左心室肥厚表现为最小强化(中位数0个节段)和最低的细胞外容积(28%)。
诊断标准与关键数值
- 配对检查中光子计数CT与心脏磁共振的左心室质量指数和左心室射血分数相关系数分别为r=0.963和r=0.947(两者P<0.001),细胞外容积相关系数r=0.868(P<0.001)。
- 晚期碘强化范围与晚期钆强化范围高度一致(r=0.998;P<0.001),逐节段一致率为99%至100%。
- 光子计数CT检测心脏磁共振晚期钆强化的AUC为0.994,敏感度99%,特异度100%。
- 光子计数CT衍生的整体细胞外容积的阅片者间一致性ICC为0.98。
临床应用与阅片要点
- 光子计数CT可评估左心室几何、功能和心肌纤维化/细胞外容积,并在同次检查中完成冠状动脉造影。
- 作者认为光子计数CT支持在心脏磁共振禁忌、不可行或无法诊断时使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Photon-counting computed tomography (PCCT) combines high spatial resolution with spectral imaging and can provide morphologic, functional, and tissue assessment in hypertrophic hearts.
OBJECTIVES: The authors investigated whether PCCT characterizes left ventricular hypertrophy (LVH) as accurately as cardiac magnetic resonance (CMR) overall and across hypertrophic phenotypes.
METHODS: Consecutive patients with LVH (n = 182; 72 with hypertrophic cardiomyopathy, 47 with amyloid transthyretin cardiomyopathy, and 63 with secondary LVH) underwent PCCT including late iodine enhancement (LIE) and PCCT-derived extracellular volume (ECV). Eighty-three patients (46%) also underwent CMR within ±12 months (median interval: -12 days). Agreement was assessed for morphofunctional indices, ECV, and LIE vs late gadolinium enhancement (LGE).
RESULTS: PCCT differentiated etiologies through distinctive tissue patterns. Transthyretin cardiac amyloidosis showed the highest left ventricular mass index (median: 104 g/m2), the greatest LIE extent (median: 17/17 segments), and the highest ECV (median: 47%). Hypertrophic cardiomyopathy showed patchy fibrosis (median 4 enhanced segments) with intermediate ECV (31%), whereas secondary LVH displayed minimal enhancement (median: 0 segments) and the lowest ECV (28%). In paired examinations, PCCT correlated closely with CMR for left ventricular mass index and left ventricular ejection fraction (r = 0.963 and r = 0.947; P < 0.001 for both) and for ECV (r = 0.868; P < 0.001). LIE extent strongly agreed with LGE extent (r = 0.998; P < 0.001); segment-wise LIE/LGE agreement was 99% to 100%, and PCCT detected CMR-LGE with excellent accuracy (AUC: 0.994; sensitivity 99%; specificity 100%). Global PCCT-derived ECV showed excellent inter-reader agreement (ICC: 0.98).
CONCLUSIONS: PCCT provides CMR-comparable assessment of ventricular geometry, function, and myocardial fibrosis/ECV while enabling coronary angiography, supporting its use when CMR is contraindicated, impractical, or nondiagnostic.
引用
- De Gori C, Aimo A, Occhipinti M, et al. Photon-Counting Computed Tomography for Tissue Characterization in Patients With a Left Ventricular Hypertrophic Phenotype. JACC Cardiovasc Imaging. 2026. PMID: 41925664. doi:10.1016/j.jcmg.2026.02.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。